comprehensive
Previous article:
Alkermes shareholders re
Next article: JPM 2024: Verve Therapeutics looks to mainstream genome editing
Next article: JPM 2024: Verve Therapeutics looks to mainstream genome editing
entertainment
explore
-
FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy
2025-09-27 22:25 -
Fauci’s Covid grilling leads GOP to weigh foreign research rules
2025-09-27 21:36 -
Biotech reporter’s notebook: A sunnier mood at JPM 2024
2025-09-27 20:53 -
Readout LOUD podcast: A CRISPR milestone, biotech mixology
2025-09-27 20:33 -
Morphosys mixed study results for blood cancer drug
2025-09-27 20:14 -
The nurse manager staffing crisis is hurting patients
2025-09-27 20:05